The aim of this review is to provide a summary on multidisciplinary scientific information obtained from medicinal plants used worldwide to treat anxiety, focusing on pharmacological and clinical studies. The bibliographical investigation was carried out by consulting five peer-reviewed worldwide database publications for references, and patents. The information gathered on plants with attributed anxiolytic properties are presented as follows: (1) plant extracts with anxiolytic properties evaluated in animal models; (2) plants with clinical trials; (3) identified active compounds in plants that have been assayed in animal models; (4) mechanism of action of anxiolytic plant extracts and compounds; and (5) registered patents for anxiolytic plant preparations. We recorded 112 plant species belonging to 63 botanical families for which the anxiolytic properties had been tested in animal models. Eleven plant species to treat general anxiety disorders as well as eleven species to treat anxiety-associated conditions, had been documented by clinical trials. Thirty-three registers for active compounds belonging to five general types of secondary metabolites had also been recorded. The mechanism of action at the central nervous system level had been determined in 33 plant species, either in their extracts or isolated compounds. Forty-seven patent registrations for plant preparations to be used for the treatment of anxiety were included.
Introduction
Anxiety disorders are considered to be a major cause of disability worldwide, and comprise generalized anxiety disorder and other commonly associated conditions, such as phobias, postmenopausal stress, post-traumatic syndrome, somatization and cognitive dysfunction, among others. Patients diagnosed with generalized anxiety disorder exhibit functional impairment as well as a tendency to develop comorbid psychiatric disorders. 1 Effective treatments for this condition are usually focused on eliminating anxiety symptoms and restoring normal function. Conventional anxiolytic drug therapy is considered to be effective, safe, and broad-spectrum in action, 2 but side effects often reduce quality of life, discouraging patients to follow medication protocols. Moreover, many of the medicines used for anxiety include antidepressants, and the use of such agents can cause troubling side effects, ie, cholinergic symptoms, weight gain, sleep disturbances, sexual dysfunction, medication dependence, or gastrointestinal problems.
The use of herbal remedies for the treatment of anxiety is an ancient practice that nowadays has become popular in Western societies. Plant-based medicines rep-resent the most popular treatment for an estimated 43% of the worldwide population that use complementary therapy to augment their treatment for anxiety disorders. 3 It is also reported that anxiety disorders has become one of the most common reasons given for trying herbal medicines. 4 However, despite their wide use, there is limited evidence for the efficacy of herbal products when observed in controlled clinical trials. In addition, many natural products are self-prescribed, and there is a lack of scientific evidence to confirm their potential benefits or to point out resulting disadvantages when they are used in combination with patented drugs, or even alone. For example, cases of liver toxicity resulting from use of Piper methysticum (kava) 5 or of Hypericum perforatum, which can cause drug interactions, 6 have been documented. A synergistic effect resulting from the presence of various active compounds in one plant acting together to produce a greater effect than that expected from individual substances has been recognized and used in very ancient traditional medicinal practices as in Ayurvedic and Chinese medicine. 7 This approach has now been accepted in modern phytotherapy, 8 and the use of plant multidrug preparations is increasing to treat anxiety, depression, and other cognitive dysfunctions. 9 
Methodology
For this review, the indicated international literature was systematically searched to identify plants with anxiolytic effects that were documented in animal models. In addition, plant species employed in clinical trials to treat generalized anxiety disorder as well as related disorders were reviewed. We also present information about active compounds isolated from plants, and the mechanism of action of plant extracts or compounds. This review also incorporates a worldwide registry of plant patents used in the treatment of anxiety.
PubMed (MedLine), NAPRALERT, and EBSCO were the worldwide databases consulted without a time limit using the terms anxiolytic plant, anxiolytic extracts, antianxiety plants, herbal treatment for anxiety, clinical trials, general anxiety disorder, etc. The Espacenet database was used to locate patents from 1967 to the present using the terms plant, herbal, and extract, and cross-linking them with anxiety and anxiolytic terms. This search was corroborated using the USPTO database. More than 400 key publications for references were consulted. Plants used worldwide to treat anxiety and pharmacologically documented, as well as those used in clinical trials and cited in peer-reviewed international manuscripts, were included. Plants excluded were those empirically used in medicinal practices of anxiety, but without documented pharmacological or scientific studies. All sources utilized were written in English.
The publications that were included in the clinical studies were only those that were validated using the proper scale that measures the severity of anxiety, ie, the Hamilton anxiety (HAMA) scale, considered to be the gold-standard diagnostic tool.
Plants with pharmacological anxiolytic effects
From ancient times, medicinal plants were employed empirically, probably universally, for the treatment of anxiety and related disorders, but pharmacological and toxicological studies rarely existed. Even today, a relatively small number of these plants have been subjected to accepted scientific evaluation for their potential anxiolytic effects. Pharmacological studies with animal models are now used to test traditionally employed plants for their effectiveness in the treatment of anxiety-like behavior. Mice and rats present practical models for testing, due to their reproducibility, control of the inbreeding selection, and rapid response, as well as the possibility to analyze either brain structures or proteins and metabolites linked to the anxiety's phenotype. 10, 11 In the past, these animal models subjected to anxiety-producing substances were mainly assessed for their behavior using the hole-board and the light-dark transition tests, because these tests presented a pharmacological specificity where nonanxiolytic psychoactive drugs did not produce false positives. 12 Nowadays, the elevated plus-maze (EPM) test is the model used to define the anxiolytic action of a plant extract in almost 80% of all scientific publications, followed by the light-dark transition (∼17%), shock-probe burying (∼4%), and hole-board (∼2%) models. The EPM test was introduced by Pellow et A total of 112 species belonging to 63 botanical families that had been subjected to in vivo animal models have been recorded in Table 1 . The anxiolytic effects of these plants were determined using the EPM model conducted in mice in most of the species. As shown in Table 1 , the Asteraceae, Fabaceae, and Lamiaceae families are the ones with a higher number of documented species. All the listed 
Human clinical studies with anxiolytic herbs
Several herbal medicines with anxiolytic effects have been subjected to clinical trials. In Table 2A , plant species with documented use to treat general anxiety disorders are presented, while those used to treat anxiety-associated conditions are recorded in Table 2B . Table 2 shows clinical trials that used a validated scale measuring the severity of anxiety, ie, the HAMA scale, considered the gold-standard diagnostic tool. 126 In addition, scales that measure how the patient is perceived symptomatologically by a physician are also included, as the Physician's Clinical Global Impression scale as well as the Clinical Global Impression-Improvement scale. These scales can measure the improvement of patients shown by reduction in the severity of symptoms. The randomness of the clinical trials is important for its reliability. The trials that were conducted using a contemporarily prescribed and accepted as effective antianxiety drug, indicated the level of effectiveness as related to the known anxiolytic drug, as well as permit a time evaluation as to the anxiolytic effects or the appearance of any adverse effects. With respect to the time of treatment and size of the sample, when compared with clinical trials with synthetic drugs -ie, such selective inhibitors of serotonin recapture as escitalopram and paroxetine, which represent first-line anxiolytic medicine as recommended by the World Federation of Societies of Biological Psychiatry, 127 -the optimum time is 8 or more weeks, if we take into consideration that general anxiety disorder ideally requires a minimum treatment of two months and frequently more. Escitalopram has been studied for 10 weeks using a sample of 177 patients, 128 and for 12 weeks with a sample of 150 patients. 129 Paroxetine was studied for 8 weeks using 237 patients. 130 It is recommended that clinical trials using plants be performed with the same periods of time and using samples of more than 80 patients so as to be in line with the standards used for anxiolytic drugs. However, studies conducted with smaller groups can be useful as a guide for larger samples and for longer periods of medication. Most of the studies conducted with plants give tolerability data (absence or low frequency of adverse effects), allowing evaluation of the benefits of medicinal plants over such synthetic drugs as benzodiazepines and of inhibitors of serotonin recapture, both of which are the most prescribed anxiolytics. It is also important to conduct studies on children, teenagers and elderly patients. Table 2B shows plants that reduce anxiety in conditions that differ from those of general anxiety disorders, and includes clinical trials using a scale to measure the severity of anxiety. Most clinical trials include small numbers, and in some cases, such as Centella asiatica 131 or Lavandula spp. 132 one dose is administered, which, if reduction of anxiety is reported, becomes preliminary data of the anxiolytic potential of the plants.
According to the aforementioned criteria, it is possible to consider rigorous studies such as the one with silexan oral lavender oil capsule conducted for 10 weeks in 221 patients, 133 and the one with Piper methysticum conducted for 8 weeks with 129 patients, 134 both having tolerability data. Two more studies reaching the required standards are those with Galphimia glauca conducted in 152 patients 135 and with Ginkgo biloba 136 in 107 patients, both including tolerability and security data.
Active compounds
A total of 33 purified natural compounds (Table 3) with proven anxiolytic activity were recorded from the 112 plants listed in Table 1 . The reported compounds include a variety of secondary metabolites, ie, flavonoids, terpenoids, alkaloids, and phenols, with the terpenoids (total 14 compounds) forming the majority of the reported purified natural anxiolytic compounds (.42%), and the flavonoids (nine compounds) forming the second major group. Other secondary metabolites such as alkaloids (five compounds), phenols (four compounds), and other derivatives were less reported.
Mechanism of action
From the literature, it is known that most of the herbal medicines that benefit anxiety disorders had effects on the gamma-aminobutyric acid (GABA) system. 184 185 GABA transaminase or glutamic acid decarboxylase inhibition has also been reported. 186 In some cases, the herbal anxiolytic action was attributed to binding with benzodiazepine receptor sites (eg, α-subunit).
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The increased GABA neurotransmission that subsequently followed had a damping effect on stimulatory pathways, which ultimately provided a psychologically calming effect. 188 In Table 4 , the mechanism of action of 33 extracts or purified compounds from herbal medicines to treat anxiety is detailed. This search was done for the 112 plants presented in Table 1 as well as for the compounds compiled in Table 3 . A total of 33 plant extracts or purified compounds were identified in several databases. On the basis of the data in Table 4 , it can be concluded that most of the plant extracts and purified anxiolytic compounds function through the GABAergic mechanism (more than 72%, 24 total entries), and the rest (nine entries) utilize a combination of adrenergic, dopaminergic, and serotonergic mechanisms.
Patent applications on plants with anxiolytic action
A patent search was conducted using Espacenet database from the European Patent Office and corroborated by the United States Patent and Trademark Office (USPTO) database. The patent information covered the keywords plant, herbal, and extract, and these were cross-linked with anxiety and anxiolytic terms. Distillation of the final search resulted in a total of 47 patent applications for plants used as anxiolytic purposes. The adopted criteria used documentation written in English in which the anxiolytic activity was clearly demonstrated, and excluded those patents either without scientific backing or written in any language other submit your manuscript | www.dovepress.com than English. The first patent in this review was granted in 1967 by a Belgian company, in which the action of glaziovine, an alkaloid isolated from Ocotea, was registered to treat anxiety and depression. It is very difficult to obtain statistics for the global market involving the commercialization of anxiolytic plants and extracts, because most of the producers and exporters of such material come from underdeveloped countries where strict governmental control of data is lacking. The purpose of this review is to offer a record of the most important worldwide anxiolytic medicinal plants with high economic impact, as expressed by patent applications.
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A total of 47 registered patent applications for anxiolytic plants were found. Of these, only seven were exclusively for the treatment of anxiety, while the rest reported medicinal use for additional disorders, basically for depression and stress. The four with the most patents are Valeriana officinalis, Piper methysticum (kava), Ziziphus jujuba (jujube), and Hypericum perforatum, each of which had five patents. Concerning these patents, 20 presented only one plant, 16 combined a mixture of other plants and isolated compounds, while six were for a plant mixed with purified compounds or extracts ( Table 5 ).
The kava root presents an interesting case. Used in various Pacific Basin countries as a traditional beverage for soporific and narcotic effects, it was introduced into the US market in the 1990s, principally as an antianxiety preparation. The bioactive kavalactones have been used for standardization in phytomedicines, acting very positively to decrease anxiety without the loss of mental acuity, as well as in dietary supplements. Although kava efficacy has been well established, in 2001several fatal cases of hepatotoxicity among Westerners who consumed kava attracted the attention of the scientific community. The Food and Drug Administration (FDA) issued Botanics: Targets a customer advisory regarding the dangers of this agent in 2002. Its use is banned in several European countries. Nevertheless, a lot of doubts surround this issue because many data do not support a hepatotoxic potential, and the affected patients reported in the literature were also on other medications. Although India possesses both an extraordinary flora and ancient knowledge based on the Ayurvedic legacy, it has no patent record in line with the criteria established. Three Indian patent applications, for Musa spp, Cassia tora, and Myristica fragrans, were excluded from our table because of a lack of scientific studies employing animals or clinical trials, despite a large body of ethnopharmacological evidence. However, a report in India indicated that 22 plants were patented for the treatment of brain and neurological disorders, occupying eighth position in the list of locally patented species, while the first position was for disorders of the digestive system, with a total of 81 species registered to 2005. 197 Korea is the country with the most patent applications for anxiolytic plants, followed by China (Figure 1 ). Both countries have a long history of growing, using, and exporting traditional plant medicines. The number of stores and people involved in the trade of medicinal herbs has been growing through the centuries. After the opening of ports to Western trade, those in the traditional herbal medicines field faced the influx of Western medicines and secured their position in the plant trade by adapting a system of patenting the herbal remedies that they produced and sold. 198 Both Brazil and Mexico have a megadiversity of flora and widespread traditional use of medicinal plants, and yet have only one patent application each. The analysis of the history of medicinal practices and uses in these two countries, with the lack of respect for indigenous knowledge, medicinal systems, and lack of official interests to establish priorities for the bioprospection of natural resources, combined with K o r e a C h in a U S A R u s s ia G e r m a n y J a p a n F r a n c e B u lg a r ia M e x ic o B r a z il I t a ly S p a in the imposition of allopathic medicines, go a long way towards explaining this situation. Ethical discussions about biopiracy and the need to respect and protect indigenous and local community knowledge and biological resources, have emerged recently. Herbal drugs are gaining attention, mainly in developing countries due to their huge potential for new medicines, and focus is growing on patents because they contain formulations with multiherb composition, which have the potential to produce desired synergistic action with fewer deleterious side effects.
In spite of the high incidence and broad impact that anxiety has on the quality of human life, today there are no available laboratory tests to diagnose this worldwide health problem. Anxiety is usually diagnosed by means of psychological assessment criteria, interpreted by observation of the patient's behavior, taking into consideration his condition, historical background, and familial occurrences. Mental health professionals can make use of the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, known as the DSM-IV, a manual published by the American Psychiatric Association with the aim of reaching a better understanding of the patient's illness and potential treatment.
Genetic factors associated with anxiety are complex and diverse. Advances in molecular biology techniques have allowed for the manipulation of gene expression within the central nervous system of mice in order to better understand the anxiety process at a molecular level. 10 In future, individualized diagnosis and treatment for anxiety patients will be possible to prescribe based on patients' genetic profiling and on the levels of specific biomarkers through proteome and metabolome approaches. Therefore, it will be possible to know the real status of the biochemical routes involved in the pathology of anxiety, much beyond that provided by the monoamine systems. A breakthrough investigation was conducted by Filiou et al in 2011, 11 in which they used endophenotype mice with a defined genetic background for high, normal, and low anxiety-related behaviors, and then compared them in terms of protein expression and presence of metabolites. The resulting proteomic and metabolomic information was combined and processed, and in silico analysis allowed for the identification of crucial metabolic networks responsible for anxiety response. They found altered levels of up to 300 proteins and metabolites between mice with high-and low-anxiety behavior, and highlighted the role of the mitochondria in modulating this action. Knowledge of mitochondrial influence in anxiety disorders is very limited. The authors proposed the mitochondria as the unifying link between energy metabolism, oxidative stress, and neurotransmission alterations observed for the anxiety behavior, indicating the mitochondria as a selective target in the development of new drugs to treat anxiety disorders.
Conclusion
Even though research is increasing in the area of psychopharmacology, until now no comprehensive review exists that explores the use of plants to treat anxiety disorders from various experimental approaches. Using a focused multidisciplinary context, as is presented here, which includes integrated information of in vivo pharmacological studies, as well as clinical trials and molecular targets, it becomes possible to obtain insights into this field and point out future directions. Although there exist several actual reported clinical trials that provide preliminary, positive evidence of anxiolytic effects, few rigorous studies of 8 weeks or more comparing the effect produced by plants with those obtained from the use of synthetic drugs are currently available. This situation clearly indicates that it is time to increase the number of experimental studies, and to conduct rigorous clinical trials with anxiolytic plants and their active compounds.
Moreover, there is still a need for scientifically based information concerning the safety, efficacy, and quality control in the use of anxiolytic plants. One example illustrating the need for quality control and analysis of toxicity is provided by the currently popular use of St John's wort. HIV patients are now told not to use this herbal remedy because it has been shown to create resistance to the currently approved HIV treatment. This is the first review to offer a compilation of registered patents for anxiolytic plant preparations around the world. One observation on patents is that it would clearly be beneficial to include rigorous clinical trials. The use of the emerging "omics" technology can open a whole new efficient way of understanding the mechanism of action by which many plant extracts and their active compounds exert their pharmacological properties, and stimulate future research with anxiolytic herbal medicines.
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